Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 coronavirus and other betacoronaviruses March 22, 2021August 8, 2022 Coronaheadsup.com Coronavirus, Health, Treatment We show that acriflavine inhibits viral replication at nanomolar concentration in cellular models, in vivo in mice and ex vivo in human airway epithelia, with broad range activity against SARS-CoV-2 and other betacoronaviruses. Full biorxiv.org preprint ** This post was originally published on March 22, 2021 **Share this:Post Related Posts: FDA on Paxlovid rebound: "there is no evidence of benefit at this time for a longer course…Australia: 58% seek advice for ongoing Covid symptomsMonkeypox: Extensive surface contamination following treatmentNorth Korea: Latest update on Covid situationPaxlovid: Covid-19 infections rebounding a few days after treatment *4 UPDATES*USA: CDC is recommending that people who experience certain new symptoms after receiving…
